King's College London

Research portal

Differential medication overuse risk of novel anti-migraine therapeutics

Research output: Contribution to journalArticle

Chonlawan Saengjaroentham, Lauren Strother, Mohammad Sultan-Jabir, Isaac Dripps, Amynah Pradhan, Peter Goadsby, Philip Holland

Original languageEnglish
Publication statusAccepted/In press - 3 May 2020


King's Authors


Medication overuse headache is estimated to affect two percent of the population, and is ranked in the top 20 most disabling disorders, due to its high level of disability. Several therapies used in the treatment of acute migraine are thought to be associated with medication overuse headache, including opioids and triptans. With limited treatment options, it is critical to determine the risk profile of novel therapies prior to their widespread use. The current study explores the potential medication overuse risk of two novel therapeutic drug classes, namely the ditans: 5-HT1F receptor agonists, and the gepants: calcitonin gene-related peptide receptor antagonists, in a preclinical model of medication overuse. Persistent exposure of mice to the 5-HT1F agonist LY344864, but not olcegepant produced a significant reduction in hindpaw and orofacial mechanical withdrawal thresholds as a surrogate readout of allodynia. In agreement, only LY344864 induced neuroplastic changes in trigeminal sensory afferents, increasing calcitonin gene-related peptide expression and basal trigeminal nociception. Our data highlight a differential medication overuse headache risk profile for the ditan and gepant classes of drugs that has important implications for their clinical use and patient education to help reduce the burden of medication overuse headache.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454